Sabatini out at MIT
Plus Avidity expands role of MacLean and updates from Exscientia, eFFECTOR, Sofinnova and more
Biologist David Sabatini has resigned his professorship at Massachusetts Institute of Technology, after the institute’s provost, biology department head, and dean of science found that he had violated MIT’s consensual sexual or romantic relationships in the workplace or academic environment policy, and recommended revocation of his tenure. Sabatini, who pioneered research into the master cell signaling regulator mTOR and co-founded KSQ Therapeutics Inc. and Navitor Pharmaceuticals Inc., resigned from the Whitehead Institute for Biomedical Research and was fired from Howard Hughes Medical Institute last August after an investigation found he had violated sexual harassment policies.
San Diego-based RNA therapeutics company Avidity Biosciences Inc. (NASDAQ:RNA) expanded the role of CFO Michael MacLean to include responsibilities as CBO. MacLean joined Avidity in May 2020 from Akcea Therapeutics Inc., where he was CFO, EVP...